Weekly Digest - Jan 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - Jan 2024
17 Jan 2024: RC48-ADC combos show efficacy in HER2+ and HER2-Low Breast Cancers
- Disitamab Vedotin (RC48-ADC), a humanized antibody-drug conjugate, demonstrated consistent efficacy and tolerability in a phase 2 study for HER2-positive or HER2-low locally advanced or metastatic breast cancer
- In the overall patient population (n=120), the treatment resulted in a median progression-free survival (PFS) of 5.7 months, an overall response rate (ORR) of 38.3%, and a disease control rate (DCR) of 64.2%
- Subgroup analysis showed a median PFS of 6.3 months for HER2-positive patients and 3.6 months for HER2-low patients, with corresponding ORRs of 42.7% and 29.0%
- Combining Disitamab Vedotin with immune checkpoint inhibitors, TKIs, or antiangiogenic compounds demonstrated enhanced efficacy, suggesting a potential future direction for the development of the antibody-drug conjugate
